ACRIVON THERAPEUTICS
Live / Applied — Extension of time to oppose received (as of 02 Apr 2026)
What this means for you
Not registered yet, but its 11 Sept 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99388151
- Mark type
- Design + words
- Filed
- 11 Sept 2025
- Published for opposition
- 03 Mar 2026
- Attorney of record
- Sara Bauer
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Protein arrays for diagnosing cancer; Pharmaceutical preparations for the prediction of drug treatment efficacy; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes; Reagents for medical purposes; Medical diagnostic reagents for use in drug-tailored efficacy predication and analysis; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting genetic predispositions; Biological preparations for the prevention and treatment of cancer, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases
- Class 042 — Scientific and technological services: Medical and scientific research in the field of oncology; Medical and scientific research in the field of proteomics, biomarker discovery, rational drug design in drug discovery, patient responder identification and indication finding, and precision medicine clinical trials based on responder identification; Biochemical analysis services in the field of biomarker discovery; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research in the field of pharmaceuticals, therapeutics, and drug formulation and delivery; Scientific research in the field of proteomics and biomarker discovery; Consulting services in the field of pharmaceutical research and development; Pharmaceutical research services; Research and development in the pharmaceutical and biotechnology fields
- Class 044 — Medical, beauty and agricultural services: Medical services; Medical testing services; Medical diagnostic testing, monitoring and reporting services; Medical testing services relating to the diagnosis and treatment of disease; Medical counseling; Providing medical information to medical professionals in the form of reports in the field of oncology and precision medicine; Medical testing for diagnostic or treatment purposes in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases; Providing a website featuring information in the field of oncology, fibrotic, inflammatory, autoimmune, metabolic, infectious, and central nervous system diseases and precision medicine health
Owner
- Acrivon Therapeutics, Inc., Watertown, MA, US
- Acrivon Therapeutics, Inc., Watertown, MA, US
Prosecution history
- 02 Apr 2026 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 03 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Mar 2026 — PUBLISHED FOR OPPOSITION
- 25 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Feb 2026 — EXAMINER'S AMENDMENT ENTERED
- 05 Feb 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 05 Feb 2026 — EXAMINERS AMENDMENT E-MAILED
- 05 Feb 2026 — EXAMINERS AMENDMENT -WRITTEN
- 04 Feb 2026 — ASSIGNED TO EXAMINER
- 03 Feb 2026 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 03 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 11 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 11 Sept 2025 — NEW APPLICATION ENTERED